Our Stocks to Watch today include Optical Systems Inc. (OTC: OPSY), NavStar Technologies Inc. (OTC: NVSR), Green Star Alternative Energy Inc. (OTC: GSAE), AlphaRx Inc. (OTCBB: ALRX), Applied DNA Sciences Inc. (OTCBB: APDN), AVANIR Pharmaceuticals Inc. (Nasdaq: AVNR), Optigenex Inc. (OTC: OPGX), Left Behind Games Inc. (OTCBB: LFBG), Trey Resources Inc. (OTCBB: TYRIA), Converted Organics Inc. (Nasdaq: COIN) and NXGen Holdings Inc. (OTCBB: NXGH).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
OPTICAL SYSTEMS INCORPORATED (OTC: OPSY)
"Up 11.76% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OPSY.php
Company Profile: http://www.otcpicks.com/optical-systems/optical-systems.htm
Optical Systems, Inc., through its operating subsidiary, Automotive Software Designers, Inc., develops technology and services for the automotive retail industry designed to maximize productivity and increase profits at auto dealerships. ASDI's flagship technology solution, Save-a-Deal, is a turnkey customer relationship management (CRM) tool for auto dealerships. Our business development center (BDC) provides a variety of services designed to help auto dealerships drive traffic to their showroom or Web site, retain customers and generate new streams of revenue.
OPSY News:
August 10 - ASDI Partners With Triple Protection Auto Care, Inc. to Sell Identity Theft Recovery Product
Innovative ID Theft product gives 'peace-of-mind' to consumers and dealers concerning the growing reality of identity theft crimes
Automotive Software Designers, Inc. (ASDI), a leading provider of software and services for the automotive retail industry, and a wholly owned subsidiary of Optical Systems, Inc. (OTC: OPSY), announced a partnership with Triple Protection Auto Care, Inc. (Tri-PAC) to market IdentiTheft®, a breakthrough identity theft solution for consumers that is sold on behalf of automotive dealers.
"We're excited to partner with an industry leading CRM services provider like ASDI," said Keith Cooper, President and CEO of Tri-PAC. "ASDI's CRM package will allow dealers to market automotive consumer products outside the scope of the F & I office. In a time where lenders are restricting the dealerships' ability to finance additional consumer products & services, ASDI's approach is refreshing."
IdentiTheft® provides a professional ID Theft Recovery Advocate Program to fully manage the restoration process and restore customers' identity to pre-event status should they become a victim of identity theft.
"We believe ASDI and Tri-PAC are a perfect fit, and anticipate rapid results," said Tri-PAC Director of Operations, Danny Madigan. "In addition, ASDI's CRM solution acts as a form of contract production - 'performance risk mitigation' for many of our dealer clients who are utilizing our Information Defense-Red Flag Compliance tool."
Under the terms of the agreement, ASDI will market the IdentiTheft® solution through its newly re-engineered business development center (BDC), which provides a broad range of customer relationship management products and services to auto dealerships.
The Federal Trade Commission received over 300,000 ID theft complaints in 2008, an increase from about 250,000 in 2007. ID theft was the biggest complaint received by the agency, and represented 26 percent of all the complaints it received in 2008. Another surprise in the 2008 statistics is that twenty-somethings are most likely to get hit with ID theft.
Nearly every day, there are new reports of sensitive personal information being lost or stolen. Identity theft leaves its victims emotionally devastated as they try to restore their good name, a process that may take years.
"There are more than 26,000 automotive dealerships and more than 7,000 recreational vehicle dealerships in the
ABOUT TRI-PAC
Incorporated in 2002, Triple Protection Auto Care, Inc. is recognized as an industry leader in providing vehicle retailers with cutting edge, market-relevant products, services and solutions. Headquartered in Centennial,
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
August 11 - NavStar Technologies, Inc. Begins Procedures to Uplist on Pinksheets, From Limited to Current Information
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo, today announced that it is undertaking all measures necessary in order to become listed as a Current Information Company on Pinksheets.com listings.
"We are pleased to announce that we will be submitting all necessary filings in order to be listed as a Current Information Company with Pinksheets.com. This is one of many steps we are planning in order to become a fully listed OTCBB company. Such a move can only prove beneficial to our shareholders in permitting us to be completely transparent and as such gain the confidence of our investors," said N. Douglas Pritt, Chairman & CEO, NavStar Technologies, Inc. "This decision is consistent with our long term plans for expansion, growth and development. Our company has come a long way and we feel that the best is yet to come."
GREEN STAR ALTERNATIVE ENERGY INCORPORATED (OTC: GSAE)
Detailed Quote: www.otcpicks.com/quotes/GSAE.php
Company Profile: http://www.otcpicks.com/Newsletter/GSAE_eProfile_091708.htm
Green Star Alternative Energy is an environmentally conscious, renewable energy producer. The Company is working to develop more than 300 MW (megawatts) of clean electricity through wind energy. The corporate revenue model is two-fold: the use of a renewable resource allows not only for the creation of environmentally friendly energy, but the granting of carbon (greenhouse gas) emission credits which may be traded and sold. Green Star is pursuing a significant opportunity to provide clean energy to the growing
GSAE News:
August 11 - CEO of Green Star Alternative Energy Conducts Exclusive Webcast Interview with The Green Baron Report
Green Star Alternative Energy, Inc. (OTC: GSAE) ("GSAE" or the "Company") announces that its CEO Mike Andric has conducted an exclusive new audio-taped webcast interview so that GSAE shareholders and the investment community can learn more about the Company’s recent developments and growth plans. Unrestricted access to the webcast is now available on the “Webcasts” page at www.TheGreenBaron.com. This webcast is also available at www.StrictlyStocks.com, "Where Wall Street speaks to the World."
The Green Baron Report also issued a new “Stock Pick” profile dated Tuesday, August 4th, 2009 to its members and is available on their website. The report focused on how Green Star is moving forward to develop wind energy projects to the under supplied market in
ALPHARX INCORPORATED (OTCBB: ALRX)
Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php
Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
ALRX News:
August 10 - AlphaRx Receives
AlphaRx Inc. (OTCBB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that it has been granted a comprehensive patent in China for its topical platform technology entitled "Vehicle For Topical Delivery of Anti-Inflammatory Compounds." The platform is an integral part of the Company's clinical stage product candidate Indaflex™.
"
In April 2006, AlphaRx licensed the global rights (with the exception of Asia and
ABOUT INDAFLEX™
Indaflex is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the symptomatic treatment of osteoarthritis. Arthritis is the most common chronic disease in
APPLIED DNA SCIENCES INCORPORATED (OTCBB: APDN)
Detailed Quote: http://www.otcpicks.com/quotes/APDN.php
Company Profile: http://www.otcpicks.com/applied-dna-sciences.htm
APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping(TM) by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators.
APDN News:
August 5 - Crystal Research Issues Executive Informational Overview® on Applied DNA Sciences
DNA Platform Technologies Provide Anti-Counterfeiting Security Solutions
Applied DNA Sciences, Inc. (OTCBB: APDN) announced that Crystal Research Associates, LLC has issued an Executive Informational Overview (EIO) on APDN. The full report can be found at www.crystalra.com. Well-known and respected on Wall Street, Jeffrey Kraws, CEO of Crystal Research Associates (Crystal), has received some of the most prestigious awards in the industry and is a frequent guest on CNN, CNBC, MSNBC, Fox Business News and Bloomberg. He has been consistently ranked as one of the leading research analysts in the pharmaceutical sector on Wall Street (StarMine), and often cited for his expert opinion on important trends and financial direction relative to security, biotech, pharmaceuticals and other key sectors.
APDN provides DNA-based security and authentication solutions to identify originals and to help protect products, brands, and intellectual property from counterfeiting and diversion. Counterfeiting is one of the fastest growing pecuniary crimes, threatening jobs and business, and endangering public health and safety. The World Customs Organization estimated that the $600 billion (2004) annual global trade in illegitimate goods is expected to double to $1.2 trillion by 2014.
Driven by its two anti-counterfeiting security platforms, SigNature DNA and BioMaterial Genotyping™, APDN can service a multitude of industries including cash-in-transit, textiles and apparel, secure documents for military and homeland security, pharmaceuticals, wine, and other luxury items. Commercial applications across a broad spectrum of industries allow APDN to minimize revenue risk concentration and create a steady stream of income.
DNA is a form of forensic evidence trusted by police and recognized by courts around the world. APDN is the ONLY company making use of the complex codes embedded in botanical DNA as the ultimate solution to counterfeiting. Unlike holograms and RFIDs, APDN's patented SigNature DNA markers:
* cannot be copied or reverse engineered
* are forensic and offer absolute authentication
* are "green," safe and affordable
APDN has recently been selected to launch its SigNature DNA Anti-Counterfeiting Program for the
ABOUT
AVANIR PHARMACEUTICALS (NASD: AVNR)
"Up 55.68% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AVNR.php
AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in
AVNR News:
August 11 - AVANIR Announces Positive Phase III Study Results for Zenvia
* Zenvia Met Primary Efficacy Endpoint in Confirmatory Trial
* Zenvia Demonstrated Improved Safety and Tolerability Profile
AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) announced that the investigational drug Zenvia™ (dextromethorphan/quinidine) met its primary efficacy endpoint in the treatment of pseudobulbar affect (PBA) in the confirmatory Phase III STAR trial. Both Zenvia 30/10 mg and 20/10 mg provided a statistically significant reduction in episode rates over the course of the study when compared to placebo (p<0.0001). In an additional analysis of the primary endpoint, at week twelve (end of study), patients in the Zenvia 30/10 mg group reported a statistically significant mean reduction of 88% from baseline in PBA episode rates (p=0.01). Also in this study, Zenvia was generally safe and well tolerated. AVANIR management will conduct a conference call to discuss this announcement on August 11 at 5:00 AM PDT (8:00 AM EDT).
"Frequent, unpredictable and often intense emotional outbursts may take a devastating toll on patients with PBA and their loved ones. The results of the STAR trial indicate that the new low dose formulation of Zenvia can substantially reduce the number of PBA episodes that these patients experience," said Jeffrey Cummings, MD, Augustus Rose Professor of Neurology at the David Geffen School of Medicine at UCLA and Steering Committee Chairman for the STAR trial. "With no FDA approved treatments currently available, there is a real unmet medical need for the estimated 2 million patients in the
"The STAR data indicate that the new low dose Zenvia formulations offer an improved safety and tolerability profile while continuing to deliver statistically significant and clinically meaningful efficacy in the treatment of PBA," said Keith Katkin, AVANIR's President and CEO. “We are very encouraged by the top-line results and we believe that the STAR data should be sufficient to address the issues outlined in the FDA approvable letter. We hope to have a full presentation of the STAR trial results at a scientific meeting later this year and plan to submit our complete response to the FDA in the first half of 2010."
Efficacy Results
The primary efficacy analysis was based on the changes from baseline in crying/laughing episode rates recorded in the patient diary. Episode counts were reported and analyzed as a rate expressed as episodes per day. The primary outcome was the additional reduction in episode rates experienced with Zenvia 30/10 mg compared to placebo. In the STAR trial, Zenvia 30/10 mg provided a 47.2% incremental reduction in episode rates compared to placebo over the course of the study (p<0.0001). In a secondary analysis of the primary endpoint, Zenvia 20/10 mg also provided a statistically significant incremental reduction of episode rates compared to placebo (p<0.0001).
An important secondary endpoint analysis was based on the change from baseline to end of study using the Center for Neurologic Studies Lability Scale (CNS-LS). The CNS-LS is a validated instrument measuring the frequency and severity of PBA. In this secondary endpoint analysis, patients receiving Zenvia 30/10 mg reported a significantly greater reduction in mean CNS-LS score compared to patients who received placebo (p=0.0002).
Additional secondary endpoints were included to help expand the Company’s understanding of the potential clinical utility of Zenvia. These additional endpoints include: 1) SF-36 Health Survey, 2) Neuropsychiatric Inventory Questionnaire (NPI-Q), 3) Beck Depression Inventory (BDI-II), and 4) Pain Rating Scale score (MS patients only). Data from these secondary efficacy endpoints, as well as additional exploratory analyses, are expected to be reported at an upcoming scientific meeting later this year.
Safety and Tolerability Results
Overall, Zenvia was generally safe and well tolerated in this study. In the STAR trial, 90.9%, 82.2% and 86.2% of patients completed the 12-week double blind phase of the study in the Zenvia 30/10 mg, Zenvia 20/10 mg and placebo groups, respectively. The most common reason for early withdrawals was due to adverse events (AEs). Early withdrawal due to AEs occurred in 3.7%, 7.8% and 1.9% for the Zenvia 30/10 mg, Zenvia 20/10 mg and placebo groups, respectively. The proportion of patients reporting at least one AE was 83.2% in the Zenvia 30/10 mg group, 80.4% in the Zenvia 20/10 mg group and 81.1% in the placebo group. Reported AEs were generally mild to moderate in nature. The most commonly reported adverse events that appeared to be more frequent than placebo were dizziness, nausea and diarrhea. While commonly reported, falls, headache, somnolence and fatigue were no different than placebo.
The proportion of patients reporting at least one serious adverse event (SAE) was 6.5% in the Zenvia 30/10 mg group, 8.8% in the Zenvia 20/10 mg group and 10.4% in the placebo group. A total of 38 SAEs occurred in 27 patients over the course of the study. Of the 38 SAEs reported in the study, only two were deemed by the investigators to be possibly or probably treatment-related; zero in the Zenvia 30/10 mg group, two in the Zenvia 20/10 mg group and zero in the placebo group. In addition, there was a numerical difference in respiratory SAEs with five patients (4.7%) in the Zenvia 30/10 mg group, three patients (2.9%) in the Zenvia 20/10 mg group and two patients (1.9%) in the placebo group experiencing respiratory SAEs.
Overall, there were seven deaths in the study, all in patients with underlying ALS. In total, three deaths occurred in the Zenvia 30/10 mg arm, three in the 20/10 mg arm and one in the placebo arm. Of the seven deaths that were reported, five of the deaths (four in the Zenvia treatments arms and one in the placebo arm) occurred at least five days after study drug had been discontinued. There was one reported death in the Zenvia 20/10 mg group that was considered possibly treatment-related, which occurred five days after study drug had been discontinued.
During the study, there were no significant changes observed in laboratory values from baseline to end of study in any treatment group. In order to evaluate the potential for respiratory depression, nocturnal oxygen saturation was measured. There was a decrease in mean nocturnal oxygen saturation of 0.7% in the Zenvia 20/10 mg group (p=0.0472); however, no difference was observed in the higher 30/10 mg dose group relative to placebo.
Cardiovascular Safety
During the course of the study, no new cardiovascular safety signals were observed. There were no clinically meaningful changes in QT interval, no reported pro-arrhythmic events and no reports of any cardiovascular SAEs.
“Overall, the STAR data would suggest that the new low dose formulation of Zenvia provides an improved safety and tolerability profile relative to the previous formulation,” said Randall Kaye, MD, AVANIR's Chief Medical Officer. “We look forward to receipt and analysis of the full data set from the double blind phase of the STAR trial as well as results from the open-label extension study to further evaluate the safety and efficacy of the new dose formulations.”
Star Trial Design
The STAR (Safety, Tolerability and Efficacy Results of AVP-923 in PBA) trial is a confirmatory Phase III trial of Zenvia in patients with pseudobulbar affect (PBA). The randomized, multi-center, international STAR trial compares active treatment with Zenvia 30/10 mg BID and Zenvia 20/10 mg BID to placebo during a three-month, double-blinded phase, followed by a three-month, open-label extension study. At the conclusion of enrollment, AVANIR had enrolled a total of 326 patients (197 with underlying ALS and 129 with underlying MS) who exhibited signs and symptoms of PBA across 52 sites in the U.S. and Latin America. A total of 110, 107 and 109 patients were randomized to the Zenvia 30/10 mg group, the Zenvia 20/10 mg group and the placebo group, respectively. The primary efficacy analysis is based on the changes in crying/laughing episode rates recorded in patient diaries. Secondary endpoints for this clinical trial include: 1) Center for Neurologic Study-Lability Scale (CNS-LS) score; 2) Neuropsychiatric Inventory Questionnaire (NPI-Q); 3) SF-36 Health Survey; 4) Beck Depression Inventory (BDI-II); and 5) Pain Rating Scale score (MS patients only). Safety and tolerability of Zenvia are determined by reporting adverse events, physical exam, vital signs, electrocardiogram, respiratory function tests and clinical assessment of clinical laboratory variables. The STAR trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA).
ABOUT PBA
Pseudobulbar affect (PBA), also known as emotional lability, is a neurologic disorder that occurs secondary to neurologic disease or brain injury causing sudden and unpredictable episodes of crying, laughing, or other emotional displays. PBA is estimated to impact approximately 2 million people in the United States with underlying neurologic conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson's disease, dementias including Alzheimer's disease, stroke, and traumatic brain injury. PBA episodes may occur when disease or injury damages the area of the brain that controls normal expression of emotion. This damage can disrupt brain signaling causing a "short circuit" and triggering involuntary PBA episodes. PBA has been shown to impair the lives of patients in both social and occupational settings. There are currently no FDA approved treatments for PBA.
ABOUT ZENVIA
Zenvia™ (dextromethorphan/quinidine) is a combination of two well-characterized compounds: the therapeutically active ingredient dextromethorphan and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways: through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. In October 2006, the Company received an approvable letter for Zenvia in the treatment of PBA. The Company is conducting a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. For more information about this trial visit www.pbatrial.com. For more information about the Agency's SPA process, see www.fda.gov/cder/guidance/3764fnl.htm. In addition, AVANIR has conducted a Phase III study of Zenvia in DPN pain where the primary endpoints were successfully met. Subsequently the Company released top-line results of a formal PK study that identified alternative lower-dose quinidine formulations of Zenvia for DPN pain intended to deliver similar efficacy and improved safety/tolerability versus the formulations previously tested for this indication. AVANIR is now engaged in discussions with the FDA under the SPA process regarding the design of the next Phase III study in DPN pain and overall program requirements.
OPTIGENEX INCORPORATED (OTC: OPGX)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OPGX.php
Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound as it core product. AC- 11® is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa.
OPGX News:
July 28 - Optigenex Inc. Announces Rollout of Activar® AC-11® Oral Supplements and Activar® AC-11® Next Generation Skin Care Products in Turkey Through Its Middle Eastern Distribution Partner Ekson Farma, Istanbul
Company Expects Commercial Sales to Begin in Early Fall 2009 Through Pharmacies and Other Healthcare Distribution Channels (Financial Terms Were Not Disclosed)
Optigenex Inc. (OTC: OPGX) announced that its partner Ekson Farma is prepared to launch its family of AC-11® oral supplements and skin care products under the brand name Activar® for distribution throughout the major pharmacies in Turkey. Under an exclusive license signed in early 2008, Ekson has invested significant capital, resources and time in determining market acceptance of Optigenex's patented technology and has also devoted considerable efforts towards clinical and scientific research to broaden the market applications for its unique anti-aging products. The agreement and subsequent commercialization by Ekson sets the stage for the introduction of AC-11® to educated and health-conscious Turkish consumers and represents another important strategic initiative in the company's plans to establish AC-11® as a recognized international brand.
All-natural, and standardized at a minimum of 8 per cent Carboxy Alkyl Esters ("CAEs(TM)"), AC-11® is the only patented aqueous extract of the Uncaria species that can make the following therapeutic claims ("DNA repair, Immune enhancement and Inhibition of pro-inflammatory agents") which are validated by a broad spectrum of scientific and clinical studies.
AC-11® already has gained a major foothold in Japan and has been introduced in other select territories of Asia as a branded ingredient used by over 100 manufacturers and distributors in a variety of anti-aging cosmetic, cosmeceutical and dietary supplement products. With their regional alliance together, Optigenex and Middle Eastern based Ekson Farma anticipate similar market penetration, growth and expansion for AC-11®
Daniel Zwiren, president and CEO of Optigenex Inc., said, "We are delighted to have a company with the scientific pedigree and reputation of Ekson Farma as part of our growing list of marketing and distribution partners. Moreover, we believe the unique scientific properties of AC-11® along with Ekson's research will allow us to grow our business rapidly in this key geographic region."
Doctor Yaman Er, president of Ekson Farma, added, "We are very pleased with the reception AC-11® has received and attribute this attention to the key differentiators of AC-11® supported by clinical and scientific studies. Those studies validate the efficacy of this all-natural ingredient, which is harvested in the Amazon Rainforest and manufactured by Centroflora Group Botucatu, Brazil. Consumer demand in our market is driven by new and result-oriented technologies. We believe our alliance with Optigenex provides us with the opportunity to introduce Turkey and the Middle East to the next major brand in oral and topical applications."
ABOUT EKSON FARMA
Founded in 1994, Ekson Farma is an applied sciences and marketing company focused on providing wellness solutions and related technologies to physicians, pharmacies and the general medical community. Ekson's strategy is to select superior and innovative products validated by clinical and scientific studies, establish consumer and physician acceptance through test marketing and ultimately distribute those products with the goal of improving the quality of life for health conscious consumers and patients. Ekson through its collaboration with research partner OKSANTE LABORATORIES is noted for its development of diagnostic tools utilizing DNA sequencing and molecular diagnostics with an emphasis on early detection of disease and DNA mutations.
LEFT BEHIND GAMES INCORPORATED (OTCBB: LFBG)
"Up 31.25% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LFBG.php
Left Behind Games, Inc. engages in the development, publishing, and distribution of video games and related products in the United States. The company develops its video game products based on the Left Behind series of novels and products. Its primary product includes LEFT BEHIND: Eternal Forces, a real time strategy game played by one person or online by up to eight players on personal computers. The company sells its products through a direct-to-store distribution channel or through distributors to Christian booksellers association and inspirational marketplaces. It markets its products in North America, Australia, Canada, Singapore, and South Africa. Left Behind Games, Inc. was founded in 2002 and is based in Murrieta, California.
LFBG News:
August 11 - Left Behind Games gains momentum in preparation for holiday season sales
Left Behind Games Inc. (OTC: LFBG), dba Inspired Media, a leading publisher of Christian video games, reports recent developments that are anticipated to provide sustainable profitability before the end of its fiscal year ending March 31, 2010. Most significant is the announcement that Jack of All Games (a Take-Two Interactive Software company) will launch distribution of the Left Behind Games product line on August 25, 2009 with the expectation that games will be available in major retail locations sometime in September. All packaging for the games has been upgraded and, in some cases, will include embossed titles and case slipcovers. Interested retailers should contact their Jack of All Games representative.
The Company recently announced that Wal-Mart will test five of its products in stores during the Christmas holiday season. Preliminary discussions indicate trial marketing will begin on September 28, 2009 and focus on a region favorable to faith-based demographics; potentially Texas. The Company plans a significant marketing push for the trial and will publish details as they become available.
CEO, Troy Lyndon, says, "We expect our bottom line profit to increase substantially in coming quarters as a result of recent aggressive efforts to implement our four-fold marketing plan. Our strategy encompasses marketing through mainstream retailers, the church marketplace, Christian stores and our upcoming online store. Our family-friendly online store will be launched before the end of the quarter, and at that time our products, in addition to more than a thousand family-friendly games, will be available for copy-protected download."
The Company currently publishes six games including Tribulation Forces, the sequel to the original game LEFT BEHIND: Eternal Forces, known as the most widely distributed Christian PC game in history. The Company's LEFT BEHIND branded games are based upon the popular novel series by Tim LaHaye and Jerry Jenkins which have sold more than 65 million books in 30 languages worldwide.
In contrast to many other PC games, Inspired Media games encourage positive decisions and actions. Rather than the usual "winning" by using weapons and killing the enemy, players are rewarded when their characters use the power of influence to bring about good rather than destruction.
TREY RESOURCES INCORPORATED (OTC BB: TYRIA)
"Up 33.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/TYRIA.php
Trey Resources is involved in the acquisition and build-out of technology and software companies. The Company's growth strategy is to acquire firms in this extensive and expanding, but highly fragmented segment, as it seeks to create substantial value for shareholders. Since June 2004, Trey has acquired SWK Technologies, Inc., Business Tech Solutions Group, Inc., Wolen Katz Associates, and AMP-BEST Consulting, Inc.
TYRIA News:
June 6 - Trey Resources Posts Second Consecutive Profitable Quarter
Visit http://bit.ly/MTS8d to view Trey Resources Inc. (OTCBB: TYRIA) recent quarterly financial report.
CONVERTED ORGANICS INCORPORATED (NASDAQ: COIN)
"Up 16.92% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/COIN.php
Converted Organics, Inc. focuses on the manufacture, sale, and distribution of natural soil amendment products combining nutritional and disease suppression characteristics. It uses organic food waste as raw material to manufacture soil amendment products. Converted Organics plans to sell and distribute these products in the agribusiness, turf management, and retail markets. The company was founded in 2003 and is headquartered in Boston, Massachusetts.
COIN News:
August 4 - Customers Report Positive Results with Converted Organics' Fertilizers
Growers, Turf Professionals Re-order Products
Converted Organics Inc. (Nasdaq: COIN) announced that customers who purchased and used the Company’s all-natural, organic fertilizers this season are reporting positive results and have placed additional orders for the remainder of the 2009 growing season. Converted Organics’ all-natural fertilizers are used on a variety of organic and conventional crops, as well as by landscape professionals.
“This is the first year I have used Converted-Organics Liquid Concentrate 1-1-1 and my cranberries are plentiful and the plant is healthy. This has been a difficult year, with little sunshine and constant rain, causing the berry size to be smaller than normal this time of year, but overall the crop looks good,” said Phil DeMoranville, owner of Kingfisher Corporation in Dartmouth, MA, who has been growing organic cranberries for 10 years. “The plant is very healthy and strong going into the berry rot season, which is very important because we cannot apply fungicides to organic crops. We have very few products to use in organic growing of cranberries and, from what I see at this time, Converted Organics is something new and has a place in organic farming.”
Neil Wendell, a third-generation golf course superintendent at New Bedford Country Club in New Bedford, MA used Converted Organics’ Liquid Concentrate 1-1-1 on his greens this season for the first time.
“We are constantly challenged by Mother Nature and local growing conditions, and we look for products that help us reduce our carbon footprint; after all, we are in the green industry. We added Converted Organics’ Liquid Concentrate 1-1-1 to our green maintenance program this year, and the result is that we have a very strong-looking plant,” said Mr. Wendell. “This is important going into our stress period of heat and humidity. We are looking for the SAR affect on the plant’s ability to tolerate stress from cultural practices, such as mowing below one-eighth of an inch, and our seasonal play at its highest, which weaken the turf and allow fungus to get a foothold during stress conditions. We have had fungus problems in the past and, from what I see at this time, we look good.”
“Testimonials from growers and turf professionals on the front lines, provide valuable insight into the performance of Converted Organics’ fertilizer products in everyday growing conditions,” said Edward J. Gildea, President of Converted Organics. “Their experiences reinforce the fact that Converted Organics’ high-quality organic fertilizers meet, and often exceed, growers’ expectations and needs.”
NXGEN HOLDINGS INCORPORATED (OTC: NXGH)
"Up 13.79% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NXGH.php
NXGen Holdings, Inc., through its wholly owned subsidiary, Green Bridge Industries, Inc., offers non-toxic, environmentally friendly cleaning products to fit the sanitation needs of the medical, agricultural, military and retail markets. The Company, through its proprietary technology, has the ability to develop 100% all natural cleaning products, which are superior to the synthetic products currently offered in the marketplace. The Company's products are safe for the surfaces it cleans, the environment, animals and humans.
NXGH News:
August 11 - NXGen Holdings, Inc.'s Subsidiary to Launch Marketing and Sales Campaign Towards the Government and Military Sector
NXGen Holdings Inc. (OTCBB: NXGH) announced that the Company's wholly owned subsidiary, Green Bridge Industries, Inc., has entered into an agreement with Leading Points Corporation to help Green Bridge secure purchase orders with various government and military agencies. Leading Points will assist the Company in developing a marketing and sales strategy for the military and government sector as well as perform a number of services for the Company to include developing national brand and licensing opportunities for its line of "green" cleaning products. The agreement will allow Green Bridge Industries to immediately introduce its product line to 34 million Americans in the military market with nearly $2 trillion in annual purchasing power. In addition, the Company will be able to reach out to the Federal Government, which, according to TargetGov.com, spends over $400 billion every year purchasing products and services of virtually every type from businesses large and small through out the United States.
Leading Points has the experience to assist Green Bridge Industries in implementing a marketing strategy targeted directly to the Federal Government, the military demographic as well as private and non-profit organizations that cater to U.S. Military personnel, both active and retired. Founded and led by Lieutenant Colonel Kevin Sullivan U.S. Army (Retired), Leading Points' concept involves drawing on established relationships and continuously building new ones among buyers and management of the military and the government. They have helped businesses of all types go from overlooking a powerful market to virtually overnight success stories.
"I look forward to bringing my network of commercial and military associates on board to assist in the development of Green Bridge Industries. Green Bridge Industries has a fantastic line of green products that I am happy to promote and bring to market," stated Kevin Sullivan, President of Leading Points Corporation.
"I am very pleased to have Leading Points working directly for us on developing relationships not only with government and military entities, but also with presenting Green Bridge Industries with national branding and licensing opportunities as well," stated William White, Chairman and CEO of NXGen Holdings, Inc.
ABOUT LEADING POINTS CORPORATION
Leading Points Corporation, founded in 2004, specializes in marketing to the military market. They are considered the experts in matters of securing placement of their clients' products in the military exchange store distribution channel as well as special promotions to the military community. The company is headquartered in Centennial, Colorado.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in
securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated one hundred thousand free trading shares by a third party for OPSY advertising and promotional services. OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com is being compensated thirty seven thousand, five hundred free trading shares by a non-controlling third party (Onyx Consulting Group) for GSAE advertising and promotional services. OTCPicks.com has previously been compensated eight thousand dollars and five thousand free trading shares for GSAE advertising and promotional services in the past. OTCPicks.com has been compensated two thousand five hundred dollars by a third party for APDN advertising and promotional services. Additionally OTCPicks.com has been compensated a total of five thousand dollars by BlueWave Advisors for multiple one week promotions of APDN. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
